包头东宝生物技术股份有限公司 2017 年第三季度报告全文 包头东宝生物技术股份有限公司 2017 年第三季度报告 2017-054 2017 年 10 月 1 包头东宝生物技术股份有限公司 2017 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 878,931,471.15 | | 833,132,333.54 | 5.50% | | 归属于上市公司股东的净资产 | 722,915,373.76 | | 718,860,039.04 | 0.56% | | （元） | | | | | | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | | ...

Financial Performance - The total operating revenue for the reporting period was CNY 162,210,667.60, an increase of 0.64% compared to the same period last year [26]. - The net profit attributable to shareholders of the listed company was CNY 12,140,956.28, representing a growth of 45.43% year-on-year [26]. - The net profit after deducting non-recurring gains and losses was CNY 10,433,237.74, up 119.60% from the previous year [26]. - The net cash flow from operating activities was CNY 1,139,582.22, a significant improvement of 111.40% compared to a net outflow of CNY 9,996,485.73 in the same period last year [26]. - The basic earnings per share were CNY 0.0263, reflecting a 45.30% increase year-on-year [26]. - Operating profit reached CNY 14,542,276.61, reflecting a significant increase of 78.92% year-on-year [52]. - The total profit amounted to CNY 14,379,511.36, which is a 45.20% increase compared to the previous year [52]. - The company reported a decrease in net cash and cash equivalents by 69.54%, totaling -¥118,978,906.86, attributed to increased dividend payments and unredeemed financial products [70]. Investment and R&D - The company is focusing on developing gelatin and collagen protein extension products to increase product added value and create new profit points [7]. - The company is investing in high-quality bone particle bases and forming strategic partnerships with key suppliers to control raw material costs and mitigate procurement risks [12]. - The R&D center has commenced operations, focusing on production process innovation to improve product quality and reduce costs, while also pursuing various certification qualifications [55]. - Research and development expenses surged by 95.60% to ¥6,427,871.18, primarily due to increased investment in new projects and collaborations [70]. - The company has 15 authorized patents, including 9 invention patents, with ongoing efforts in technology development and intellectual property protection [44]. Market Strategy and Expansion - The company aims to establish "Yuan Su Bone Peptide" as a leading brand in the collagen protein industry and will actively expand the market through brand promotion and developing distributor resources [8]. - The company is leveraging the "Healthy China" initiative to accelerate the development of the collagen protein market and increase market share [8]. - The company acknowledges the risk of mismatched returns on investments during market expansion efforts in the collagen protein sector [8]. - The company achieved significant growth in collagen protein product sales, indicating a strong market expansion potential [37]. - The company is expanding its gelatin production capacity and exploring new application fields to capture market opportunities and enhance profitability [53]. Financial Management - The company has committed to an investment project with a total investment amount of RMB 25,357.3 million, of which RMB 19,199.8 million has been invested, achieving a progress rate of 75.72% [86]. - The total investment amount for the reporting period reached CNY 101,887,196.92, representing an increase of 66.56% compared to the previous year [80]. - The company has temporarily supplemented working capital with RMB 30 million of idle raised funds, which has been returned within 12 months [87]. - The company reported a total of 25,720 in financial products, with a principal amount of 19,220 and a return of 77.24% [1]. - The company plans to use up to 70 million yuan of temporarily idle raised funds to purchase principal-protected, liquid short-term bank financial products, with an investment period not exceeding 12 months [1]. Corporate Governance and Compliance - The company did not distribute cash dividends or issue bonus shares for the half-year period [99]. - The company has no major litigation or arbitration matters during the reporting period [104]. - The company has no significant related party transactions during the reporting period [107]. - The company’s half-year financial report was not audited [101]. - The financial statements prepared by the company comply with the requirements of the accounting standards, accurately reflecting its financial position, operating results, and cash flows [191]. Environmental Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities [120]. - The company has a total COD discharge limit of 86.96 tons, with actual discharge levels below the regulatory standards [121]. - The company has established an environmental protection management committee to oversee compliance and risk management [121]. - The company has a wastewater treatment facility that operates in compliance with national standards [121]. Shareholder Information - The total number of shareholders at the end of the reporting period is 18,494 [132]. - The largest shareholder, Inner Mongolia Dongbao Economic and Trade Co., Ltd., holds 32.36% of shares, totaling 149,143,800 shares [132]. - The company has a total of 15,947,844 restricted shares, with 1 share released during the reporting period [130]. - The executives' shares are subject to a 25% annual unlock limit during their tenure [129]. - The company did not experience any changes in its controlling shareholder during the reporting period [134].

包头东宝生物技术股份有限公司 2017 年第一季度报告全文 包头东宝生物技术股份有限公司 2017 年第一季度报告 2017-017 2017 年 04 月 1 包头东宝生物技术股份有限公司 2017 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 非经常性损益项目和金额 √ 适用 □ 不适用 单位：元 公司负责人王军、主管会计工作负责人赵秀梅及会计机构负责人(会计主管 人员)杜丽声明：保证季度报告中财务报表的真实、准确、完整。 2 包头东宝生物技术股份有限公司 2017 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 76,889,222.52 | 79,177,840.62 ...

Market Expansion and Strategy - The company focuses on gelatin and collagen products, which are in high demand due to increasing health awareness and supportive national policies, leading to a rapidly expanding market capacity [6]. - The company plans to enhance its market presence by promoting its collagen peptide brand, Yuan Su Bone Peptide, and expanding into new markets, although there may be risks of mismatched returns on investment [7]. - The company aims to maintain its leading position in the modern collagen field by leveraging diverse application areas and expanding into emerging markets [7]. - The company is participating in various professional exhibitions to promote its products and develop distributor resources to increase market share [7]. - The company is focusing on expanding its market presence through participation in major trade exhibitions and enhancing brand visibility [54]. - The company plans to focus on export business, specifically in the sales of bone gelatin and collagen-related products, and will completely abandon any business that competes with the company after its listing [136]. - The company aims to establish itself as a leading brand in the collagen industry by enhancing its marketing efforts for terminal collagen products and developing its own brand products [112]. - The company plans to continue expanding its market presence and invest in new product development [1]. Financial Performance - The company's operating revenue for 2016 was ¥316,593,978.88, representing an increase of 8.45% compared to ¥291,916,097.74 in 2015 [22]. - The net profit attributable to shareholders in 2016 was ¥19,226,957.17, a significant increase of 226.46% from ¥5,889,584.53 in 2015 [22]. - The basic earnings per share rose to ¥0.0417 in 2016, up 187.59% from ¥0.0145 in 2015 [22]. - The company reported a total of ¥7,131,038.57 in government subsidies for 2016, compared to ¥3,801,438.62 in 2015 [28]. - The company achieved operating profit of CNY 17,976,818.28, a significant increase of 380.92% year-on-year [36]. - The company’s gelatin and collagen product sales increased due to rising market demand, with a notable decrease in production costs for gelatin [36]. - The company’s total revenue for 2016 was approximately CNY 316.59 million, representing an increase of 8.45% compared to CNY 291.92 million in 2015 [65]. - The company reported a net profit of CNY 19,974,342.53 for 2016, from which 10% was allocated to statutory surplus reserves [129]. Research and Development - The company has a strong focus on R&D, with significant investments in technology development and partnerships with institutions like the Chinese Academy of Sciences [43]. - The company launched 8 independent R&D projects in 2016, enhancing production processes and supporting cost reduction and quality improvement [57]. - The company completed several R&D projects, including the development of a collagen hydrolysate preparation process and the purification of bone collagen peptides [75][76]. - The research and development center is nearing completion, aimed at establishing a domestic collagen results transformation platform [52]. - The company is committed to improving management levels and preparing talent in sales, production, and procurement to meet the challenges of expanded capacity [8]. Operational Challenges and Management - The company is currently in the trial production phase of its fundraising projects, which will further expand its business scale and may pose management and operational challenges [8]. - Fixed asset depreciation costs are expected to increase significantly after the completion of fundraising projects, potentially leading to risks of not meeting expected benefits if production capacity is not fully utilized [9]. - The company is enhancing its human resources management to build a talent pipeline and optimize performance management systems, aiming to improve operational capabilities [121]. - The company is focusing on improving user service management by transitioning from a product supplier to a solution provider, aiming to enhance user loyalty and service response [117]. Shareholder and Dividend Information - The profit distribution plan includes a cash dividend of 0.25 RMB per 10 shares, with no bonus shares issued, based on a total of 460,874,108 shares [10]. - The total cash dividend distributed in 2016 was CNY 11,521,852.70, accounting for 100% of the distributable profit [126]. - The company had a distributable profit of CNY 82,361,925.61 as of December 31, 2016, after accounting for previous dividends and reserves [129]. - The company has committed to maintaining its dividend policy to ensure shareholder returns [133]. Environmental and Social Responsibility - The company has established an environmental protection management committee and implemented a comprehensive environmental management system to ensure compliance with national standards [169]. - The total approved discharge amount for COD is 86.96 tons, with actual emissions within the regulatory limits [169]. - The company has not reported any instances of exceeding discharge standards, maintaining compliance with the "Comprehensive Wastewater Discharge Standards" (GB8978-1996) level one standard [169]. - The company has established a charity fund for joint health, contributing products and funds to local welfare institutions [167]. - The company emphasizes employee welfare by providing health check-ups and training to enhance employee skills [167]. Strategic Goals and Future Outlook - The company aims to become a core supplier of raw materials in the collagen biotechnology field, focusing on market expansion and brand building in 2017 [111]. - The company is committed to enhancing its brand competitiveness and resource integration capabilities to achieve its strategic goal of becoming a world-class modern collagen biotechnology enterprise [108]. - The biopharmaceutical industry is projected to experience rapid growth due to favorable policies and increasing health awareness among the population [103]. - The company plans to build a domestic collagen results transformation platform to accelerate technology upgrades and enhance profitability through internal and external R&D collaborations [115].

Financial Performance - Total revenue for the reporting period was CNY 67,545,342.61, an increase of 16.21% year-on-year[7]. - Net profit attributable to shareholders was CNY 4,694,768.29, a significant increase of 288.51% compared to the same period last year[7]. - The net profit after deducting non-recurring gains and losses was CNY 2,293,849.23, up 168.95% year-on-year[7]. - The basic earnings per share for the reporting period was CNY 0.0102, representing a growth of 67.21% compared to the previous year[7]. - The company achieved operating revenue of CNY 228,719,290.62, a year-on-year increase of 14.14%[31]. - Operating costs amounted to CNY 183,827,430.68, reflecting a year-on-year increase of 12.79%[31]. - The company reported an operating profit of CNY 11,544,156.94, up 157.68% compared to the previous year[31]. - Net profit attributable to shareholders reached CNY 13,043,306.62, representing a year-on-year growth of 149.79%[31]. - Sales expenses increased by 41.56% to CNY 14,545,084.75, while management expenses rose by 47.83% to CNY 20,916,033.49[31]. - Non-operating income increased by 92.29% to CNY 4,012,857.53, primarily due to higher government subsidies received[31]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 772,322,871.99, a decrease of 0.99% compared to the previous year[7]. - Cash and cash equivalents decreased by 46.99% to ¥135,127,540.18 from ¥254,904,076.16 due to expenditures on fundraising projects[28]. - Total current assets decreased from CNY 473,368,303.89 to CNY 325,231,644.59, a reduction of about 31%[71]. - The total liabilities decreased from CNY 73,497,083.27 to CNY 59,646,483.50, reflecting a decline of about 19%[73]. - The company's retained earnings increased from CNY 72,045,514.30 to CNY 78,175,709.31, an increase of approximately 8%[74]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,804[19]. - The largest shareholder, Baotou Dongbao Industrial (Group) Co., Ltd., holds 32.36% of shares, totaling 149,143,800 shares, with 53,840,000 shares pledged[19]. - The second-largest shareholder, Guohua Life Insurance Co., Ltd. - Wan Neng No. 3, holds 3.80% of shares, totaling 17,513,134 shares[20]. - The company has not engaged in any repurchase transactions among the top 10 shareholders during the reporting period[21]. - The top 10 shareholders include a mix of natural persons and institutional investors, with significant stakes held by family members[20]. Investment and R&D - The company is actively researching the terminal market for collagen and plans to enrich its product line to boost sales[12]. - The company is advancing several R&D projects, including the development of medical collagen hydrolysate production processes and collagen peptide purification[34]. - The company has developed a new organic fertilizer production process from gelatin production waste, with plans to apply for a patent and complete industrial design within the year[35]. - The company has initiated the application process for collagen health food product approvals, which is currently progressing well[17]. - The company plans to continue expanding its market presence and investing in new product development to sustain growth in future quarters[89]. Market Strategy - The company plans to enhance its brand strategy and expand its market presence, particularly in the bone health sector[11]. - The company is actively promoting its "Yuan Su Bone Peptide" product through online and offline channels, resulting in increased brand awareness and sales growth[42]. - The company is leveraging the "Healthy China 2030" initiative to expand its market applications and enhance product quality and service offerings[43]. - The company is focusing on the "Healthy China" strategy, enhancing market development efforts and aiming to expand user base while improving quality[44]. - The company has established partnerships with traders across multiple provinces, leading to a significant increase in collagen sales and successful international market expansion[41]. Compliance and Governance - The company is actively enhancing management and training to comply with new legal regulations[17]. - The new Food Safety Law and its regulations will impose higher requirements on the health food industry, presenting new challenges[16]. - The company has committed to not transferring shares acquired in the current issuance for 12 months post-listing, ensuring stability in shareholder equity[53]. - The company has established a commitment to manage fundraising effectively to mitigate the risk of shareholder return dilution[55]. - The company will not allow any form of competition or related transactions that could harm its interests[56]. Cash Flow - Cash inflow from operating activities totaled CNY 132,127,133.12, an increase from CNY 116,848,070.05 in the previous period, representing a growth of approximately 13.5%[95]. - Net cash flow from operating activities was CNY 11,298,378.57, down from CNY 21,976,187.68, indicating a decline of about 48.7%[96]. - Cash inflow from investment activities amounted to CNY 887,992,980.72, with cash outflow totaling CNY 1,016,299,809.65, resulting in a net cash flow of -CNY 128,306,828.93[99]. - Cash inflow from financing activities was CNY 1,500,000.00, while cash outflow was CNY 4,268,085.62, leading to a net cash flow of -CNY 2,768,085.62[100].

包头东宝生物技术股份有限公司 2016 年半年度报告全文 包头东宝生物技术股份有限公司 2016 年半年度报告 2016-057 2016 年 08 月 1 包头东宝生物技术股份有限公司 2016 年半年度报告全文 第一节 重要提示、释义 本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料 不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性、完整性承担个别及连带责任。 所有董事均已出席了审议本报告的董事会会议。 公司负责人王军、主管会计工作负责人赵秀梅及会计机构负责人(会计主管 人员)杜丽声明：保证本半年度报告中财务报告的真实、完整。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 2016 | 半年度报告 1 | | | --- | --- | --- | | 第一节 | 重要提示、释义 1 | | | 第二节 | 公司基本情况简介 4 | | | 第三节 | 董事会报告 | 6 | | 第四节 | 重要事项 10 | | | 第五节 | 股份变动及股东情况 | 14 | | 第六节 | 董事、监事、高级管理人员情况 | 15 | | 第七节 ...

Financial Performance - Total revenue for Q1 2016 was ¥79,177,840.62, representing a 19.79% increase compared to ¥66,099,850.07 in the same period last year[7] - Net profit attributable to shareholders was ¥3,251,197.08, up 23.59% from ¥2,630,616.05 year-on-year[7] - The company reported a basic earnings per share of ¥0.0141, reflecting a 6.02% increase from ¥0.0133 in the same period last year[7] - Operating profit reached ¥3,302,763.81, reflecting a growth of 66.35% compared to the same period last year[30] - Gelatin sales volume increased by 21.68%, contributing to the overall revenue growth[30] - Non-recurring gains and losses contributed ¥1,460,387.11 to net profit, an increase of ¥364,087.11 from the previous year[31] - The company achieved total operating revenue of ¥79,177,840.62, a year-on-year increase of 19.79%[30] - Net profit for the period was ¥3,251,197.08, compared to ¥2,630,616.05 in the same period last year, reflecting a growth of approximately 23.6%[71] Cash Flow and Financial Position - Net cash flow from operating activities was -¥14,225,704.66, a decrease of 407.51% compared to ¥4,626,035.79 in the previous year[7] - Cash received from operating activities increased by 396.96% to ¥8,544,629.65, primarily due to employee stock ownership plan funds[30] - The net cash flow from operating activities was -14,201,660.88 CNY, compared to 4,587,102.54 CNY in the previous period, indicating a significant decline in operational performance[81] - The total cash outflow from operating activities reached 50,743,486.03 CNY, significantly higher than the previous period's 31,519,377.34 CNY[81] - The company reported a total cash and cash equivalents balance of 225,517,511.68 CNY at the end of the period, down from 254,861,523.31 CNY at the beginning[84] Assets and Liabilities - Total assets at the end of the reporting period were ¥769,495,403.94, down 1.35% from ¥780,043,276.75 at the end of the previous year[7] - Current assets decreased to CNY 445,700,897.73 from CNY 473,368,303.89, primarily due to a reduction in cash and inventory levels[62][64] - Total liabilities decreased to CNY 59,750,197.06 from CNY 73,497,083.27, showing a reduction of approximately 18.7%[64][65] - The company's equity attributable to shareholders increased to CNY 709,745,206.88 from CNY 706,546,193.48, reflecting a growth of about 0.31%[65] Marketing and Product Development - The company is shifting its marketing strategy from a "single product supplier" model to a "product + solution" model to create more value for downstream users[11] - The company has launched a new product, Round Collagen Peptide, targeting the bone and joint health market, with initial sales showing promise[12] - The company plans to focus on B2B sales of collagen products, expanding partnerships with distributors and trade companies[33] - New marketing strategies, including "B2C+C" model and community experience stores, have improved sales of collagen products[34] - The company initiated three new R&D projects aimed at enhancing gelatin and collagen applications[34] Investments and Future Plans - The company plans to enhance production efficiency through increased automation and smart technology investments[10] - The company is investing in a halal bone particle production base to meet raw material demands and aims to become a leading player in the halal gelatin market in China[15] - The company plans to accelerate the investment progress of fundraising projects to achieve expected benefits as soon as possible[46] - The company aims to enhance the management of raised funds to improve capital utilization efficiency and operational profitability[46] - The project for producing 600 tons/year of gelatin using bone enzyme technology has progressed to continuous experimental production, with product quality meeting contractual requirements[36] Shareholder Information - The top shareholder, Baotou Dongbao Industrial (Group) Co., Ltd., holds 32.36% of the shares, amounting to 74,571,900 shares, with 18,703,226 shares pledged[19] - The company has a total of 13,643 common shareholders at the end of the reporting period[19] - The company commits to strictly execute its dividend policy to ensure shareholder returns[46] - The company plans to distribute cash dividends of CNY 0.3 per 10 shares, totaling CNY 6,913,111.62 million[56] Research and Development - The company has signed a technical cooperation agreement with the Institute of Physics and Chemistry of the Chinese Academy of Sciences to ensure successful industrialization of the new technology[17] - Research on the inhibitory effects of collagen peptides on bone loss in tail-suspended rats has shown significant results, providing a theoretical basis for astronaut-specific product development[38] - The company has applied for a patent for a collagen peptide health product targeting menopausal syndrome, with plans for industrialization once conditions are met[39] - The project on improving gelatin color through adsorption and decolorization technology has achieved expected results and is set for production application in 2016[40] Operational Challenges - The company has faced unforeseen challenges during the industrialization process that require further breakthroughs[17] - The company is actively optimizing processes and equipment selection for the new technology, accumulating valuable experimental data for future industrialization[17]

Financial Performance - The company's operating revenue for 2015 was CNY 291,916,097.74, representing a 16.28% increase compared to CNY 251,053,920.13 in 2014[26]. - The net profit attributable to shareholders for 2015 was CNY 5,889,584.53, which is a 20.49% increase from CNY 4,888,090.74 in 2014[26]. - The net cash flow from operating activities improved significantly to CNY 45,574,107.27, a 472.44% increase from a negative CNY 12,236,765.88 in 2014[26]. - The total assets of the company at the end of 2015 were CNY 780,043,276.75, marking a 47.02% increase from CNY 530,569,565.29 at the end of 2014[26]. - The net assets attributable to shareholders increased by 107.47% to CNY 706,546,193.48 from CNY 340,555,790.27 in 2014[26]. - The basic earnings per share for 2015 were CNY 0.0290, up 17.41% from CNY 0.0247 in 2014[26]. - The company reported a quarterly revenue of CNY 91,533,785.79 in Q4 2015, which was the highest among the four quarters[28]. - The company experienced a decrease in net profit attributable to shareholders in Q4 2015, which was CNY 667,915.20, down from CNY 2,630,616.05 in Q1 2015[28]. - The company received government subsidies amounting to CNY 3,801,438.62 in 2015, compared to CNY 2,772,438.68 in 2014[32]. - The total operating revenue for 2015 was CNY 291,916,097.74, representing a 16.28% increase from CNY 251,053,920.13 in 2014[59]. - Net profit attributable to shareholders reached CNY 5,889,584.53, reflecting a growth of 20.49% year-on-year[36]. - The increase in revenue was primarily driven by improved gelatin market conditions, with sales volume rising significantly[36]. - Non-operating income contributed CNY 367.29 million to net profit, up 46.17% from the previous year[37]. Investment and Expansion - The company plans to invest in automation and smart technology to enhance production efficiency and reduce costs, aiming for a "cost reduction and efficiency increase" strategy[6]. - The company is actively pursuing industry consolidation opportunities to expand production capacity and enhance market share through capital operations[6]. - The company raised CNY 37,559.30 million through a private placement to fund new projects, including a new gelatin production line[46]. - The construction of the new gelatin production facility is expected to boost annual production capacity to 10,000 tons by the end of 2016[41]. - The company is preparing for the industrialization of its R&D results, including a project on the reuse of gelatin production waste, which has completed technical route verification[74]. - The company is currently engaged in the construction of the Binhe New District project, with cumulative investment reaching ¥33,027,689.69, indicating ongoing expansion efforts[85]. - The project for producing 3,500 tons of new products has an adjusted total investment of RMB 253.57 million, with RMB 46.39 million invested to date, representing 18.30% of the investment progress[88]. - The R&D center construction project has an investment of RMB 52.02 million, with RMB 12.28 million invested to date, representing 23.60% of the investment progress[89]. Product Development and Innovation - The company launched a new product, Round Collagen Peptide, targeting the bone and joint health market, with initial sales showing positive trends[7]. - The company is collaborating with the Institute of Physics and Chemistry of the Chinese Academy of Sciences to ensure the successful industrialization of a new gelatin production process[12]. - The company has ongoing R&D projects, including the development of collagen peptide health products and a project on the inhibitory effects of collagen peptides on tumor growth, with a patent application submitted[73]. - The company achieved a stable production process for gelatin color improvement technology, expected to be applied in production in 2016[74]. - The company is focused on enhancing market expansion efforts to boost sales revenue and future profitability[135]. - The company aims to accelerate the development of new products, including medical collagen hydrolysates and bone collagen peptides, to create new profit growth points[111]. - The company is committed to continuous technical innovation and lean production management to improve product quality and reduce costs, focusing on differentiated product offerings based on gelatin and collagen[100]. Marketing and Customer Engagement - The company is focusing on building a brand strategy to enhance market recognition and customer trust in its products[6]. - The company is implementing a dual-channel marketing strategy, combining offline and online sales to increase product accessibility and consumer education[9]. - The company launched community experience stores in Baotou to expand the distribution and promotion of the Yuansu collagen peptide brand, conducting 35 promotional events[49]. - The company plans to implement a "B2C+C" marketing model, enhancing consumer education and expanding community business models, including "conference marketing" and "community experience stores" to strengthen user engagement[106]. - The establishment of an official e-commerce platform will be prioritized, aiming to create a vertical ecosystem that integrates users, supply chains, sales, and services, thereby reducing user acquisition costs and enhancing user conversion capabilities[106]. Financial Management and Shareholder Relations - The company plans to distribute cash dividends of 0.3 yuan per 10 shares to shareholders, with a capital reserve conversion of 1:1[14]. - The cash dividend for 2015 represents 117.38% of the net profit attributable to shareholders, indicating a strong return to investors[132]. - The company has maintained a consistent cash dividend policy over the past three years, with increasing amounts distributed to shareholders[132]. - The company emphasizes the importance of safety, efficiency, and quality in its production processes through automation and centralized control[121]. - The company has committed to a profit distribution policy to ensure returns for shareholders, mitigating the dilution of immediate returns[135]. - The company has undertaken to compensate shareholders for any losses incurred due to non-fulfillment of commitments[134]. - The company is focused on maintaining shareholder value through strategic share management and planned releases[179]. Governance and Compliance - The company has established a commitment to maintain a high level of transparency and accountability in its operations[134]. - The company has committed to fulfilling all promises made during the acquisition and restructuring processes[133]. - The audit firm Dahuahui Certified Public Accountants has been retained for four consecutive years, with an audit fee of 330,000 RMB[144]. - The company has not issued any non-standard audit reports during the reporting period[142]. - The company has made commitments to ensure no competition with its own products from controlling shareholders and related parties[138]. - The company has no non-operating fund occupation by controlling shareholders or related parties during the reporting period[141]. Human Resources and Management - The company is focused on talent development and incentive systems to enhance employee engagement and support strategic goals[116]. - The management team includes experienced professionals with backgrounds in finance, technology, and management, enhancing the company's strategic direction[194]. - The company emphasizes the importance of human resources management, with a dedicated HR director overseeing personnel strategies[199]. - The management team is committed to maintaining compliance and enhancing operational efficiency through their diverse skill sets[200]. - The company is actively involved in the development of its human resources, ensuring that its workforce is well-managed and aligned with corporate goals[199].

Financial Performance - Total operating revenue for the reporting period was ¥58,123,697.28, representing a year-on-year growth of 7.00%[7] - Net profit attributable to shareholders was ¥1,208,400.68, a significant increase of 201.25% compared to the same period last year[7] - Basic earnings per share for the reporting period was ¥0.0061, reflecting a growth of 201.25% compared to the previous year[7] - The company achieved operating revenue of CNY 200,382,311.95, a year-on-year increase of 16.11%, driven primarily by a 38.36% increase in gelatin sales[22] - Net profit attributable to the parent company reached CNY 5,221,669.33, marking a significant growth of 63.72% year-on-year[20] - The operating profit for the third quarter was ¥1,054,669.50, a significant recovery from a loss of ¥1,932,214.78 in the same period last year[61] - Net profit for the third quarter was ¥1,208,400.68, compared to a net loss of ¥1,193,469.63 in the previous year, marking a turnaround[61] - The cumulative operating revenue for the year-to-date was ¥200,382,311.95, up from ¥172,579,221.82 in the same period last year, reflecting a growth of approximately 16.1%[68] - The net profit for the third quarter was CNY 5,221,669.33, representing a significant increase of 63.73% from CNY 3,189,407.70 in the previous year[70] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥21,976,187.68, up 204.05% year-on-year[7] - The company reported a net cash flow from operating activities of CNY 21,976,187.68, a turnaround from a negative cash flow of CNY -21,120,594.25 in the previous year[76] - The total assets at the end of the reporting period reached ¥533,140,524.52, an increase of 0.48% compared to the previous year[7] - The total current assets decreased to CNY 248,055,918.11 from CNY 302,417,067.51, indicating a reduction of approximately 18%[52] - The company's cash and cash equivalents dropped significantly from CNY 50,286,195.65 to CNY 8,059,188.80, a decline of about 84%[52] - Total cash and cash equivalents at the end of the period decreased to ¥8,028,748.20 from ¥51,310,947.91, reflecting a net decrease of ¥42,250,160.20[81] Costs and Expenses - Operating costs rose to CNY 162,989,198.68, reflecting an 18.15% increase compared to the previous year[22] - The company’s financial expenses increased by 19.05% compared to the previous year[22] - The company incurred operating costs of CNY 162,844,309.29, which is an increase from CNY 137,819,900.35 in the previous year, indicating a rise of 18.14%[72] - Cash outflow for purchasing goods and services was ¥44,309,049.79, down from ¥73,514,876.69 in the previous period, indicating improved cost management[79] - Employee compensation payments increased to ¥21,574,024.06 from ¥19,797,175.10, reflecting a 9% rise in labor costs[80] - Tax payments rose to ¥16,673,384.16 from ¥10,047,097.55, indicating a 66.5% increase in tax obligations[80] Shareholder Information - The total number of shareholders at the end of the reporting period was 10,878[12] - The largest shareholder, Baotou Dongbao Industrial (Group) Co., Ltd., holds 37.75% of the shares, amounting to 74,571,900 shares[12] - The company is focusing on maintaining stable and healthy development to protect shareholder interests through the planned share buyback[48] Market and Competition - The company faces risks from intensified competition in the gelatin market and fluctuations in the collagen market[10] - The company has made significant progress in expanding its gelatin business, with a notable increase in customer numbers and gelatin sales during the reporting period[23] - The collagen product "Yuan Su" has been repositioned to target the middle-aged and elderly joint health market, with sales showing month-on-month growth[25] Investments and Projects - The company reported a substantial increase in construction in progress, rising by 3456.52% to CNY 60,833,508.33, primarily due to investments in new gelatin technology projects[19] - The company successfully raised CNY 375.593 million through a private placement to fund new gelatin projects and a research center, which will enhance production capacity and product quality[32] - The company is actively seeking partnerships to advance the industrialization of its research projects related to gelatin and collagen products[32] Research and Development - The company completed the process design and optimization of the pilot line for the preparation of gelatin nanofiber non-woven fabric based on electrospinning technology[33] - The research on the inhibitory effect of collagen peptides on bone loss in tail-suspended rats showed significant improvement in bone microstructure, supporting the application prospects of bovine collagen peptides[33] - The company has completed the R&D content for the development of health products for menopausal syndrome and the study of collagen peptides with different molecular weights promoting bone growth, and is preparing for industrialization[34] Risk Management - There have been no significant changes in important risk factors affecting future operations, as detailed in the 2015 semi-annual report[35] - The company reported a net profit warning for the upcoming reporting period, indicating potential significant changes compared to the previous year[48] Marketing and Customer Relations - The company has established a vertical e-commerce platform to enhance brand promotion and marketing, aiming to reduce user acquisition costs and improve user conversion rates[27] - A total of 30 community promotion events for "Yuan Su" have been held, significantly increasing product awareness and customer loyalty[28] - The establishment of a customer service center and logistics department has improved customer relationship management and support[23] - The company has participated in major industry events to enhance brand recognition and customer loyalty in the pharmaceutical and health product sectors[24]

包头东宝生物技术股份有限公司 2015 年半年度报告 2015-038 2015 年 08 月 1 包头东宝生物技术股份有限公司 2015 年半年度报告全文 第一节 重要提示、释义 包头东宝生物技术股份有限公司 2015 年半年度报告全文 本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料 不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性、完整性承担个别及连带责任。 所有董事均已出席了审议本报告的董事会会议。 公司负责人王军、主管会计工作负责人赵秀梅及会计机构负责人(会计主管 人员)杜丽声明：保证本半年度报告中财务报告的真实、完整。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、释义 | 2 | | --- | --- | --- | | 第二节 | 公司基本情况简介 | 5 | | 第三节 | 董事会报告 | 9 | | 第四节 | 重要事项 | 19 | | 第五节 | 股份变动及股东情况 | 26 | | 第六节 | 董事、监事、高级管理人员情况 | 30 | | 第七节 | 财务报告 | 32 | | 第八节 | 备查文件目 ...